Precipio (NASDAQ:PRPO – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare Precipio to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.
Valuation & Earnings
This table compares Precipio and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Precipio | $27.76 million | -$360,000.00 | -34.69 |
| Precipio Competitors | $19.23 billion | $301.67 million | -1.65 |
Precipio’s rivals have higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Precipio has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Precipio’s rivals have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.
Insider and Institutional Ownership
10.4% of Precipio shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 16.6% of Precipio shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Precipio and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -4.12% | -7.84% | -5.37% |
| Precipio Competitors | -7.87% | -135.89% | -1.58% |
Analyst Ratings
This is a summary of recent recommendations for Precipio and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| Precipio Competitors | 1880 | 7755 | 13395 | 833 | 2.55 |
As a group, “Healthcare Providers & Services” companies have a potential upside of 12.77%. Given Precipio’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Precipio has less favorable growth aspects than its rivals.
Summary
Precipio rivals beat Precipio on 9 of the 13 factors compared.
About Precipio
Precipio is a diagnostics company focused on hematologic cancers and other complex diseases. It provides specialized pathology and laboratory testing services to help physicians identify and characterize blood disorders and malignancies. The company also develops and sells diagnostic products for use by clinical laboratories. Its HemeScreen platform offers molecular testing for genetic mutations associated with blood cancers, while its broader product offerings support laboratories seeking to perform specialized diagnostic tests.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
